Bayer to invest $2.2B in new drug plant in Ohio

 Bayer AG announced on Friday its plans to invest up to $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio, the United States.

According to the German healthcare group, the new plant is expected to create about 600 permanent jobs, in addition to 1,500 construction jobs. The modular campus will combine drug substance and drug product manufacturing with advanced digital technologies to support Bayer's portfolio in oncology, cardiovascular, and renal care.

"Bayer has long seen the United States as a key manufacturing base and innovation hub. This landmark investment underscores our commitment," CEO Bill Anderson noted.

https://breakingthenews.net/Article/Bayer-to-invest-dollar2.2B-in-new-drug-plant-in-Ohio/67226862

'Medicare de-fangs new drug pricing model'

 

The Trump administration rolled out the final version of a new Medicare payment model aimed at lowering the prices of drugs administered in doctors’ offices to match those paid in countries overseas.

President Trump has made lower drug prices a signature part of his administration’s affordability agenda. The Global Benchmark for Efficient Drug Pricing (GLOBE) model requires drug companies to offer a rebate if a price exceeds rates in certain countries. But the final version is significantly scaled back from when it was first proposed.     It’s now estimated that the GLOBE model will save $440 million over seven years — a 96 percent reduction from the proposed version, which estimated nearly $12 billion in savings over the same period.   The payment model is mandatory, but there is a myriad of exemptions, most notably if a company entered a separate deal with the White House for “most-favored-nation” pricing in Medicaid.     In the end, only three companies are covered by the final model, a decrease from about 40 firms estimated in the proposed rule.  “The government has crafted it in such a way that it will touch almost no drugs and deliver almost no savings,” drug industry consultant Brian Reid wrote Wednesday.     To qualify for GLOBE, a drug must account for more than $100 million in traditional Medicare Part B spending per year.     The final version of the model only covers a handful of drugs; Centers for Medicare and Medicaid Services (CMS) now estimates that less than 1 percent of eligible Part B drug spending is initially targeted by GLOBE.    “At CMS, we’re focused on more than promises to make healthcare more affordable — we’re taking action to pilot a new approach to lower costs and strengthen the quality of care while preserving medical innovation,” CMS Administrator Mehmet Oz said in a statement.  https://thehill.com/newsletters/healthcare/6124862-medicare-globe-drug-pricing-scaled-back/

FDA says Evolus Jeuveau Instagram promotion is 'false or misleading'

  orders corrective marketing response within 15 working days

https://finviz.com/stock?t=EOLS&p=d

Qiagen (QGEN) Stock Surges 7.3% Amid Advanced Acquisition Talks

 On October 02, 2026, Qiagen NV (NYSE: QGEN) shares jumped 7.3% following reports that negotiations with a U.S.-listed molecular testing company have advanced toward a potential acquisition at a "realistic premium." This development comes amid ongoing strategic review efforts involving private equity interest from firms such as TPG Inc. and Bain Capital.

The recent 7.3% rise in Qiagen’s stock price reflects growing market optimism fueled by reports that at least one potential buyer is in advanced talks to acquire the company for a premium price. This follows Qiagen’s strategic review process, which has attracted attention from private equity heavyweights like TPG Inc. and Bain Capital. The involvement of Moelis & Co. and Goldman Sachs as financial advisors underscores the seriousness of these discussions. Such a potential transaction could reshape Qiagen’s future, providing liquidity to shareholders and possibly accelerating growth through new ownership or strategic partnerships.

Qiagen NV is a Netherlands-based leader in molecular biology solutions, specializing in sample-to-insight technologies for life sciences research and molecular diagnostics. Its product portfolio includes nucleic acid extraction kits, assays, instrumentation, and bioinformatics software. Operating primarily in the healthcare sector under the Medical Diagnostics & Research industry, Qiagen serves a global customer base including academic, pharmaceutical, and clinical laboratories. The company’s market capitalization stands at $9.26 billion, reflecting its significant footprint in the healthcare diagnostics space.

https://www.gurufocus.com/news/9107895/qiagen-qgen-stock-surges-73-amid-advanced-acquisition-talks

Biogen reports 52-week Phase 2 continued efficacy, consistent safety for lupus

 

Biogen reports 52-week Phase 2 AMETHYST data showing continued efficacy, consistent safety for cutaneous lupus drug litifilimab

• Phase 3 litifilimab results in cutaneous lupus expected in the first half of 2027.

https://finviz.com/stock?t=BIIB&p=d

Eli Lilly wins FDA approval for Jaypirca as first-line treatment for certain leukemias

 

Eli Lilly wins FDA approval for Jaypirca as first-line treatment for certain adults with previously untreated CLL/SLL without 17p deletion

• Approval expands Jaypirca's U.S. label and potential market in chronic lymphocytic leukemia and small lymphocytic lymphoma.

https://finviz.com/stock?t=LLY&p=d

 

Musk’s 250-kW Nvidia power target and completed launch tripleheader lift SpaceX shares

• Benzinga at 1:40 a.m. highlighted Musk’s 250-kW Starmind-Nvidia power target.
• Musk said higher power could benefit both orbital and ground-based AI systems.
• SPCX gained about 1% overnight, then accelerated sharply after the 9:30 open.
• Falcon Heavy’s 11:53 p.m. NROL-97 launch completed three missions within 13 hours.
• The launch run included Crew-13, Transporter-18 and four successful booster landings.
• Transporter-18 carried Google’s Project Suncatcher TPU prototype, reinforcing orbital-AI positioning.
• TIKR’s 9:37 a.m. Google-TPU headline amplified the positive regular-session reaction.

https://finviz.com/stock?t=SPCX&ty=c&ta=1&p=d